Skip to main content
. 2024 Aug 8;17(8):1047. doi: 10.3390/ph17081047

Figure 2.

Figure 2

Predicted pharmacokinetic profiles of tacrolimus following intravenous (IV) infusion (light) and oral (PO) (bold) administration are illustrated for healthy volunteers (yellow), recipients only (red), donors only (blue), and both donor and recipient expressing CYP3A5 (*1/*1) (green).